肿瘤细胞治疗研究
英文原题：Beyond the blood: expanding CAR T cell therapy to solid tumors.
嵌合抗原受体（CAR）T 细胞治疗是免疫治疗领域的一项变革性进展，在血液系统恶性肿瘤中取得成功，并越来越多地应用于自身免疫性疾病。
嵌合抗原受体（CAR）T细胞疗法是免疫治疗领域的变革性进展，在血液系统恶性肿瘤治疗中取得成功，且应用日益拓展至自身免疫性疾病。在实体瘤治疗近十年成果相对有限之后，近期临床试验和患者病例报告也开始显示CAR-T治疗胶质母细胞瘤及其他难治实体瘤的积极结果。本观点文章旨在探讨这些最新成果背后的原因，并讨论如何通过CAR工程化和合成生物学等不同策略维持并拓展这些进展。此外，我们还批判性分析如何利用这些突破保持发展势头，并扩大CAR T细胞在多种实体瘤中的治疗影响。
Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advancement in immunotherapy, triumphing against hematological malignancies and, increasingly, autoimmune disorders. After a decade of relatively modest results for solid tumors, recent clinical trials and patient reports have also started to yield promising outcomes in glioblastoma and other challenging solid tumor entities. This Perspective seeks to explore the reasons behind these latest achievements and discusses how they can be sustained and expanded through different strategies involving CAR engineering and synthetic biology. Furthermore, we critically analyze how these breakthroughs can be leveraged to maintain momentum and broaden the therapeutic impact of CAR T cells across a variety of solid tumor landscapes.
MEMBER ACCOUNT
登录成功会直接打开下一页。
